ScripMerger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu
ScripAlthough Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it
Pink SheetThe US Food and Drug Administration is in the early phases of reconsidering the long-standing class-wide “black box” warning for antipsychotics citing increased mortality in older adults with dementia
ScripCullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer